| 产品名称： | Mycobacterium neworleansense Schinsky et al. |
|---|---|
| 商品货号： | TS214376 |
| Deposited As： | Mycobacterium fortuitum da Costa Cruz |
| Strain Designations： | Mf 465 W6705, DSM 44679, JCM 15659 |
| Isolation： | Tissue, human scalp wound infection, New Orleans, LA, USA, By RJ Wallace, 1987 |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | freeze-dried |
| Storage Conditions： | Frozen: -80°C or colder Freeze-Dried: 2°C to 8°C Live Culture: See Propagation Section |
| Preceptrol®： | no |
| Type Strain： | yes
Ref  Schinsky MF, et al. Taxonomic variation in the Mycobacterium fortuitum third biovariant complex: description of Mycobacterium boenickei sp. nov., Mycobacterium houstonense sp. nov., Mycobacterium neworleansense sp. nov. and Mycobacterium brisbanense sp. nov. and recognition of Mycobacterium porcinum from human clinical isolates.. Int. J. Syst. Evol. Microbiol. 54: 1653-1667, 2004. PubMed: 15388725 |
| Comments： | Biovariant 3 |
| Medium： | ATCC® Medium 44: Brain Heart Infusion Agar/Broth |
| Growth Conditions： | Temperature: 37°C
Atmosphere: Aerobic |
| Name of Depositor： | RJ Wallace |
| Chain of Custody： | ATCC |
| References： | Silcox VA, et al. Identification of clinically significant Mycobacterium fortuitum complex isolates. J. Clin. Microbiol. 14(6): 686-691, 1981. PubMed: 7037841 Wallace RJ J, et al. Clinical disease, drug susceptibility, and biochemical patterns of the unnamed third biovariant complex of Mycobacterium fortuitum. J. Infect. Dis. 163: 598-603, 1991. PubMed: 1995732 Schinsky MF, et al. Taxonomic variation in the Mycobacterium fortuitum third biovariant complex: description of Mycobacterium boenickei sp. nov., Mycobacterium houstonense sp. nov., Mycobacterium neworleansense sp. nov. and Mycobacterium brisbanense sp. nov. and recognition of Mycobacterium porcinum from human clinical isolates.. Int. J. Syst. Evol. Microbiol. 54: 1653-1667, 2004. PubMed: 15388725 Schinsky MF, et al. Taxonomic variation in the Mycobacterium fortuitum third biovariant complex: description of Mycobacterium boenickei sp. nov., Mycobacterium houstonense sp. nov., Mycobacterium neworleansense sp. nov. and Mycobacterium brisbanense sp. nov. and recognition of Mycobacterium porcinum from human clinical isolates.. Int. J. Syst. Evol. Microbiol. 54: 1653-1667, 2004. PubMed: 15388725 |
| Cross References： | Nucleotide (GenBank) : X65529 M.fortuitum 16S rRNA (TS214376) Nucleotide (GenBank) : U86086 Mycobacterium fortuitum superoxide dismutase (SOD) gene, partial cds Nucleotide (GenBank) : AY012575 Mycobacterium neworleansense strain W6705 16S ribosomal RNA gene, partial sequence Nucleotide (GenBank) : AY457068 Mycobacterium fortuitum subsp. fortuitum strain TS214376 16S ribosomal RNA gene, partial sequence |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | Mycobacterium neworleansense Schinsky et al. |
|---|---|
| 商品货号： | TS214376 |
| Deposited As： | Mycobacterium fortuitum da Costa Cruz |
| Strain Designations： | Mf 465 W6705, DSM 44679, JCM 15659 |
| Isolation： | Tissue, human scalp wound infection, New Orleans, LA, USA, By RJ Wallace, 1987 |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | freeze-dried |
| Storage Conditions： | Frozen: -80°C or colder Freeze-Dried: 2°C to 8°C Live Culture: See Propagation Section |
| Preceptrol®： | no |
| Type Strain： | yes
RefSchinsky MF, et al. Taxonomic variation in the Mycobacterium fortuitum third biovariant complex: description of Mycobacterium boenickei sp. nov., Mycobacterium houstonense sp. nov., Mycobacterium neworleansense sp. nov. and Mycobacterium brisbanense sp. nov. and recognition of Mycobacterium porcinum from human clinical isolates.. Int. J. Syst. Evol. Microbiol. 54: 1653-1667, 2004. PubMed: 15388725 |
| Comments： | Biovariant 3 |
| Medium： | ATCC® Medium 44: Brain Heart Infusion Agar/Broth |
| Growth Conditions： | Temperature: 37°C
Atmosphere: Aerobic |
| Name of Depositor： | RJ Wallace |
| Chain of Custody： | ATCC |
| References： | Silcox VA, et al. Identification of clinically significant Mycobacterium fortuitum complex isolates. J. Clin. Microbiol. 14(6): 686-691, 1981. PubMed: 7037841 Wallace RJ J, et al. Clinical disease, drug susceptibility, and biochemical patterns of the unnamed third biovariant complex of Mycobacterium fortuitum. J. Infect. Dis. 163: 598-603, 1991. PubMed: 1995732 Schinsky MF, et al. Taxonomic variation in the Mycobacterium fortuitum third biovariant complex: description of Mycobacterium boenickei sp. nov., Mycobacterium houstonense sp. nov., Mycobacterium neworleansense sp. nov. and Mycobacterium brisbanense sp. nov. and recognition of Mycobacterium porcinum from human clinical isolates.. Int. J. Syst. Evol. Microbiol. 54: 1653-1667, 2004. PubMed: 15388725 Schinsky MF, et al. Taxonomic variation in the Mycobacterium fortuitum third biovariant complex: description of Mycobacterium boenickei sp. nov., Mycobacterium houstonense sp. nov., Mycobacterium neworleansense sp. nov. and Mycobacterium brisbanense sp. nov. and recognition of Mycobacterium porcinum from human clinical isolates.. Int. J. Syst. Evol. Microbiol. 54: 1653-1667, 2004. PubMed: 15388725 |
| Cross References： | Nucleotide (GenBank) : X65529 M.fortuitum 16S rRNA (TS214376) Nucleotide (GenBank) : U86086 Mycobacterium fortuitum superoxide dismutase (SOD) gene, partial cds Nucleotide (GenBank) : AY012575 Mycobacterium neworleansense strain W6705 16S ribosomal RNA gene, partial sequence Nucleotide (GenBank) : AY457068 Mycobacterium fortuitum subsp. fortuitum strain TS214376 16S ribosomal RNA gene, partial sequence |
